Catalog No.
VMG52001
Species reactivity
Mouse
Host species
Mouse
Isotype
IgG2a, kappa
Clonality
Monoclonal
Target
Mesothelin, Pre-pro-megakaryocyte-potentiating factor, Megakaryocyte-potentiating factor, MPF, Mesothelin, cleaved form, Msln, Mes, Mpf
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
Q61468
Applications
ELISA, FCM, Neutralization
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Clone ID
Ab237
Targeted CD47 checkpoint blockade using a mesothelin-directed antibody construct for enhanced solid tumor-specific immunotherapy., PMID:40402266
[Preliminary study of mesothelin-loaded paclitaxel nanoparticles for ultrasound molecular imaging and treatment of ovarian cancer]., PMID:40375590
Molecular Mechanisms of Tumor Progression and Novel Therapeutic and Diagnostic Strategies in Mesothelioma., PMID:40362535
Generating potent and persistent antitumor immunity via affinity-tuned CAR-T cells targeting mesothelin., PMID:40341217
Development and optimization of Eva1 (MPZL2) targeting chimeric antigen receptor T cells., PMID:40341026
Advancing pancreatic cancer therapy by mesothelin-specific nanobody conjugation., PMID:40275270
Anti-Tumor Efficacy of a Mesothelin-Based Nanovaccine in a KPC Orthotopic Mouse Model of Pancreatic Cancer., PMID:40266223
Evaluating therapeutic plasma exchange and protease inhibitors as mechanisms to reduce soluble mesothelin., PMID:40240561
Systemic therapy with the infectivity-selective oncolytic adenovirus by targeting mesothelin., PMID:40226846
Selective activation of interleukin-2/interleukin-15 receptor signaling in tumor microenvironment using paired bispecific antibodies., PMID:40132909
Potent and durable control of mesothelin-expressing tumors by a novel T cell-secreted bi-specific engager., PMID:40081946
Uncovering potential targets for antibody-drug conjugates in the treatment of gynecologic malignancies., PMID:40046734
Efficacy of natural killer T and gammadelta T cells in mesothelin-targeted immunotherapy of pancreatic cancer., PMID:39995672
Targeting Mesothelin Enhances Personalized Neoantigen Vaccine Induced Antitumor Immune Response in Orthotopic Pancreatic Cancer Mouse Models., PMID:39887656
Development of a novel molecular probe for visualizing mesothelin on the tumor via positron emission tomography., PMID:39878895
Randomized Phase II Study of Bevacizumab with Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant/Refractory High-Grade Ovarian Cancer (NCI Trial)., PMID:39836408
A humanized anti-MSLN×4-1BB bispecific antibody exhibits potent antitumour activity through 4-1BB signaling activation and fc function without systemic toxicity., PMID:39806351
Conditionally activated immunotoxins with prolonged half-life can enhance the anti-tumor activity., PMID:39603436
Preclinical evaluation of 89Zr/177Lu-labeled amatuximab for theranostic application in pancreatic ductal adenocarcinoma., PMID:39542119
Development of a CD39 nanobody and its enhancement to chimeric antigen receptor T cells efficacy against ovarian cancer in preclinical studies., PMID:39431011
rhIL-7-hyFc, a long-acting interleukin-7, improves efficacy of CAR-T cell therapy in solid tumors., PMID:39043602
T cell-redirecting antibody for treatment of solid tumors via targeting mesothelin., PMID:38858494
A Bispecific Antibody That Targets the Membrane-Proximal Region of Mesothelin and Retains High Anticancer Activity in the Presence of Shed Mesothelin., PMID:38853444
Tofacitinib to prevent anti-drug antibody formation against LMB-100 immunotoxin in patients with advanced mesothelin-expressing cancers., PMID:38706610
A bispecific antibody that targets the membrane-proximal region of mesothelin and retains high anticancer activity in the presence of shed mesothelin., PMID:38647528
Mesothelin CAR-T cells expressing tumor-targeted immunocytokine IL-12 yield durable efficacy and fewer side effects., PMID:38641176
Mesothelin antigen density influences anti-mesothelin chimeric antigen receptor T cell cytotoxicity., PMID:38349311
Early Immune Remodeling Steers Clinical Response to First-Line Chemoimmunotherapy in Advanced Gastric Cancer., PMID:38319303
Tumor resistance to anti-mesothelin CAR-T cells caused by binding to shed mesothelin is overcome by targeting a juxtamembrane epitope., PMID:38227666
M9657 Is a Bispecific Tumor-Targeted Anti-CD137 Agonist That Induces MSLN-Dependent Antitumor Immunity without Liver Inflammation., PMID:38091375
Assessment of Novel Mesothelin-Specific Human Antibody Domain VH-Fc Fusion Proteins-Based PET Agents., PMID:38027361
Ex vivo pleural effusion cultures to study chimeric antigen receptor T cell cytotoxicity in an immunocompetent environment., PMID:37875122
Preclinical assessment of a novel human antibody VH domain targeting mesothelin as an antibody-drug conjugate., PMID:37771390
Mesothelin-targeted CAR-T therapy combined with irinotecan for the treatment of solid cancer., PMID:37612388
An engineered T-cell engager with selectivity for high mesothelin-expressing cells and activity in the presence of soluble mesothelin., PMID:37456982
Rapid nanobody-based imaging of mesothelin expressing malignancies compatible with blocking therapeutic antibodies., PMID:37388728
NAV-003, a bispecific antibody targeting a unique mesothelin epitope and CD3ε with improved cytotoxicity against humoral immunosuppressed tumors., PMID:37146241
High mesothelin expression by immunohistochemistry predicts improved survival in pleural mesothelioma., PMID:37040900
Safety and activity of anti-mesothelin antibody-drug conjugate anetumab ravtansine in combination with pegylated-liposomal doxorubicin in platinum-resistant ovarian cancer: multicenter, phase Ib dose escalation and expansion study., PMID:36564099
Pan-Cancer Analysis Identifies Tumor Cell Surface Targets for CAR-T Cell Therapies and Antibody Drug Conjugates., PMID:36428765
Immunotherapy for hepatobiliary cancers: Emerging targets and translational advances., PMID:35961708
Immunotherapy targeting mesothelin in acute myeloid leukemia., PMID:35946307
Anti-mesothelin CAR-T immunotherapy in patients with ovarian cancer., PMID:35925286
Construction of a 124I-Labeled Specific Antibody for the Noninvasive Detection of Mesothelin-Overexpressing Tumors., PMID:35904514
Chimeric antigen receptor T cells engineered to recognize the P329G-mutated Fc part of effector-silenced tumor antigen-targeting human IgG1 antibodies enable modular targeting of solid tumors., PMID:35902133
A Novel PD-L1-Containing MSLN Targeting Vaccine for Lung Cancer Immunotherapy., PMID:35795680
Highly active CAR T cells that bind to a juxtamembrane region of mesothelin and are not blocked by shed mesothelin., PMID:35512094
Construction of a Large Size Human Immunoglobulin Heavy Chain Variable (VH) Domain Library, Isolation and Characterization of Novel Human Antibody VH Domains Targeting PD-L1 and CD22., PMID:35464476
89Zr-3,2-HOPO-Mesothelin Antibody PET Imaging Reflects Tumor Uptake of Mesothelin-Targeted 227Th-Conjugate Therapy in Mice., PMID:35422447
Insufficiency of compound immune checkpoint blockade to overcome engineered T cell exhaustion in pancreatic cancer., PMID:35210305
For research use only. Not for human or drug use.
